COVID-19

Novacyt Group: PathFlow® technology and knowledge underpin our drive for continued innovation

Advancing technology and a unique wealth of knowledge are the driving forces behind innovative development in our PathFlow® portfolio of diagnostic tests for infectious diseases. Our latest addition to the range – the PathFlow® SARS-CoV-2 IgG – is an easy-to-use, rapid, lateral flow test for the detection of COVID-19 antibodies. It’s a natural evolution in the Novacyt Group’s range of COVID-19 diagnostic solutions, building on our growing expertise in this field, plus our ability to maximise the potential of our technologies [...]

Read more...

PathFlow®: Future innovation of COVID-19 Lateral Flow Testing

PathFlow®: Future innovation of COVID-19 Lateral Flow Testing Advancing technology and a unique wealth of knowledge are the driving forces behind innovative development in our PathFlow® portfolio of diagnostic tests for infectious diseases. This includes innovative product development in our PathFlow® portfolio – part of our Microgen Bioproducts division – where the new SARS-CoV-2 IgG rapid test is a natural addition to a fast-growing range of assays for the rapid diagnosis of infectious diseases. PathFlow® COVID-19 testing solutions: As the demands for [...]

Read more...

Evolution of testing and sequencing during COVID-19 is vital to future pandemic control

The advances in testing and genome sequencing during the COVID-19 pandemic will be crucial to predicting and managing future pandemics, according to scientific discussion during the NovaTalk webinar on February 26. What’s more, the expanse of science over the past 15 months could now be applied to tackling the growing worldwide incidence of antibiotic resistance. Prof. Sharon Peacock, Director of the COVID-19 Genomics UK Consortium and Professor of Public Health and Microbiology at the University of Cambridge, said: “I’m not afraid [...]

Read more...

SARS-CoV-2 Mutations – Cause for Concern?

SARS-CoV-2 Mutations – Cause for Concern? The accumulation of genetic mutations is a normal part of viral evolution. Mutations change the sequence of the viral genome, creating different ‘variants.’ While some mutations might be silent, with no visible clinical effect, others might have implications for disease transmission, severity, reinfection potential, and immunity. SARS-CoV-2 variants A recently described clinically significant mutation has been termed N501Y, which put simply means that the amino acid ‘N’ at position 501 of the spike protein has [...]

Read more...

Learn more about COVID-19 antibody testing

Learn more about our range of COVID-19 solutions and how they could help with your diagnostic needs. As we enter 2021, we also move into a new phase of the COVID-19 pandemic. Health services must be prepared to respond to new challenges, including the resurgence of the virus, the emergence of new strains, coordinating the roll-out of vaccination programmes, and supporting patients with ‘long covid1.’ The development of reliable mass testing services is crucial in limiting the spread of COVID-19. Novacyt’s [...]

Read more...

What does the emergence of new SARS-CoV-2 variants mean for testing?

What does the emergence of new SARS-CoV-2 variants mean for testing? The UK has recently been at the centre of considerable media attention due to the detection of a large number of COVID-19 cases caused by a new variant of the viral pathogen. This new SARS-CoV-2 variant, has been the subject of particular interest because it is associated with higher transmission rates. It has also been cited as the primary reason for introducing tighter restrictions over Christmas, a period usually [...]

Read more...

The impact of the COVID-19 pandemic on other diseases

Despite the introduction of protective measures, the COVID-19 pandemic has continued to take hold across the world. The latest data from the World Health Organisation indicates that over 40 million cases and 1.1 million deaths have been reported, with the spread of SARS-CoV-2 continuing to accelerate1. Aside from the direct implications on individuals, their families, and our collective lifestyles, there are also profound indirect effects of rising infection rates. These include barriers to accessing essential healthcare, mental health impacts, limited [...]

Read more...

COVID-19 in the winter season – overcoming new challenges with the Winterplex™

Distinguishing COVID-19 infection from other respiratory illnesses is of crucial importance in controlling the spread of the disease. This is especially true during the winter months, where there is a surge in flu cases as well as other illnesses. The genesig® SARS-CoV-2 Winterplex enables clinicians to simultaneously test for COVID-19 and other winter illnesses, providing reliable results in under two hours.   As we enter the winter months of 2020, there are several unknowns about how the severity and spread of COVID-19 [...]

Read more...

Want to know more about Novacyt’s Near-Patient Testing System?

Novacyt’s Near-Patient Test System (NPTS) for COVID-19 Introduction The value of testing for COVID-19 is well documented not only in the UK, but globally as we reflect on how the disease has spread and impacted countries differently. Whilst testing is widely accepted as the greatest weapon we currently have against the SARS-CoV-2 virus, implementation has not been without its challenges as various issues have limited healthcare systems in being able to reach their targets for desired testing output, as well as [...]

Read more...

Revolutionising your testing with exsig™ COVID-19 Direct

Hello! Welcome back to our latest blog. All departments have been working tirelessly to find an innovative solution following the bottle-neck of scarce raw materials that clinicians require to test.  SARS-CoV-2 is a continuing pandemic and the demand for the hard to source raw materials continues to be a challenge for many laboratories. Here at Primerdesign we are fully focused on supporting global efforts in the fight against this deadly disease.  Early and accurate diagnosis is pivotal in disease control.  We are [...]

Read more...